Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    A new revision tag v3.6.6 is displayed, replacing v3.6.5. This indicates a routine update to the page's underlying version rather than a substantive change to study details.
    Difference
    0.1%
    Check dated 2026-08-30T21:41:35.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    The page's platform revision was updated from v3.6.4 to v3.6.5, indicating a maintenance release of the ClinicalTrials.gov interface. This reflects an underlying software update rather than a change to study information.
    Difference
    0.0%
    Check dated 2026-08-09T10:56:33.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    The revision label was updated to v3.6.4, indicating a new build of the page. This likely reflects maintenance or bug fixes rather than changes to the study information.
    Difference
    0.0%
    Check dated 2026-07-25T23:31:00.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.2 to v3.6.3, reflecting a new build of the page.
    Difference
    0.0%
    Check dated 2026-07-04T13:25:56.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    The page's revision version was updated from v3.6.0 to v3.6.2, signaling a subsequent update to the page's content or presentation.
    Difference
    0.0%
    Check dated 2026-06-27T07:38:12.000Z thumbnail image
  9. Check
    100 days ago
    Change Detected
    Summary
    The page now indicates no further participant recruitment and introduces new user-help sections for reading the study record and joining, along with a revision label; a formatting change to the Intervention/Treatment heading is also applied.
    Difference
    0.4%
    Check dated 2026-06-13T04:32:55.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.